

Gilles Peytavin

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4483052/gilles-peytavin-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

54
papers

989
citations

15
h-index

31
g-index

58
ext. papers

1,259
ext. citations

4.9
avg, IF

3.65
L-index

#	Paper	IF	Citations
54	Intermittent two-drug antiretroviral therapies maintain long-term viral suppression in real life in highly experienced HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 1893-1897	5.1	
53	Efficacy and tolerability of combined antiretroviral treatment with bicitegravir/emtricitabine/tenofovir alafenamide initiated at the time of primary HIV infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 2484-2485	5.1	0
52	Placental transfer of doravirine, a recent HIV-1 NNRTI in the ex vivo human cotyledon perfusion model. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 2364-2367	5.1	2
51	A disseminated Mycobacterium marinum infection in a renal transplant HIV-infected patient successfully treated with a bedaquiline-containing antimycobacterial treatment: A case report. <i>International Journal of Infectious Diseases</i> , 2021 , 107, 176-178	10.5	0
50	Improvement of HIV-associated neurocognitive disorders after antiretroviral therapy intensification: the Neuro+3 study. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 743-752	5.1	3
49	Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial-authorsResponse. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 277-279	5.1	1
48	Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 477-481	5.1	
47	Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. <i>Lancet Infectious Diseases</i> , 2021 ,	25.5	66
46	Reply to Yan and Muller, "Captisol and GS-704277, but Not GS-441524, Are Credible Mediators of Remdesivir Nephrotoxicity". <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	3
45	Usefulness of therapeutic drug monitoring of rilpivirine and its relationship with virologic response and resistance in a cohort of naive and pretreated HIV-infected patients. <i>British Journal of Clinical Pharmacology</i> , 2020 , 86, 2404-2413	3.8	2
44	Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 2376-2380	5.1	18
43	Failure of hydroxychloroquine pre-exposure prophylaxis in COVID-19 infection? A case report. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 2706-2707	5.1	3
42	Characterization of drug resistance and the defective HIV reservoir in virally suppressed vertically infected children in Mali. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 1272-1279	5.1	0
41	Placental transfer of Letemovir & Maribavir in the ex vivo human cotyledon perfusion model. New perspectives for in utero treatment of congenital cytomegalovirus infection. <i>PLoS ONE</i> , 2020 , 15, e0232140	3.7	8
40	Placental transfer of the integrase strand inhibitors cabotegravir and bicitegravir in the ex-vivo human cotyledon perfusion model. <i>Aids</i> , 2020 , 34, 2145-2149	3.5	6
39	Pharmacokinetics of lopinavir/ritonavir oral solution to treat COVID-19 in mechanically ventilated ICU patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 2657-2660	5.1	10
38	Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection. <i>Antiviral Research</i> , 2020 , 181, 104866	10.8	24

37	Removal of Remdesivir & Metabolite GS-441524 by Hemodialysis in a Double Lung Transplant Recipient with COVID-19. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	16
36	Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study-authorsResponse. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 3699-3700	5.1	1
35	Placental transfer of Letemovir & Maribavir in the ex vivo human cotyledon perfusion model. New perspectives for in utero treatment of congenital cytomegalovirus infection 2020 , 15, e0232140		
34	Placental transfer of Letemovir & Maribavir in the ex vivo human cotyledon perfusion model. New perspectives for in utero treatment of congenital cytomegalovirus infection 2020 , 15, e0232140		
33	Placental transfer of Letemovir & Maribavir in the ex vivo human cotyledon perfusion model. New perspectives for in utero treatment of congenital cytomegalovirus infection 2020 , 15, e0232140		
32	Placental transfer of Letemovir & Maribavir in the ex vivo human cotyledon perfusion model. New perspectives for in utero treatment of congenital cytomegalovirus infection 2020 , 15, e0232140		
31	Placental transfer of Letemovir & Maribavir in the ex vivo human cotyledon perfusion model. New perspectives for in utero treatment of congenital cytomegalovirus infection 2020 , 15, e0232140		
30	Placental transfer of Letemovir & Maribavir in the ex vivo human cotyledon perfusion model. New perspectives for in utero treatment of congenital cytomegalovirus infection 2020 , 15, e0232140		
29	"Real life" use of raltegravir during pregnancy in France: The Coferal-IMEA048 cohort study. <i>PLoS ONE</i> , 2019 , 14, e0216010	3.7	3
28	Concentration-response model of rilpivirine in a cohort of HIV-1-infected naive and pre-treated patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 1992-2002	5.1	3
27	Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS-163 ETRAL Study. <i>Pharmacotherapy</i> , 2019 , 39, 514-520	5.8	2
26	Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 2742-2751	5.1	17
25	Higher Atazanavir Plasma Exposure in Rats is Associated with Gut Microbiota Changes Induced by Cotrimoxazole. <i>Current Drug Metabolism</i> , 2019 , 20, 898-906	3.5	1
24	Metabolic syndrome and endocrine status in HIV-infected transwomen. <i>Aids</i> , 2019 , 33, 855-865	3.5	5
23	A New Mechanism of Resistance of Human Immunodeficiency Virus Type 2 to Integrase Inhibitors: A 5-Amino-Acid Insertion in the Integrase C-Terminal Domain. <i>Clinical Infectious Diseases</i> , 2019 , 69, 657-667	11.6	15
22	Chronic hepatitis E in a heart transplant patient: sofosbuvir and ribavirin regimen not fully effective. <i>Antiviral Therapy</i> , 2018 , 23, 463-465	1.6	20
21	Population pharmacokinetics of Rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine/tenofovir/emtricitabine. <i>European Journal of Clinical Pharmacology</i> , 2018 , 74, 473-481	2.8	5
20	Placental transfer of elvitegravir and cobicistat in an ex-vivo human cotyledon double perfusion model. <i>Aids</i> , 2018 , 32, 321-325	3.5	8

19	Bariatric surgery in HIV patients: experience of an Obesity Reference Center in France. <i>Surgery for Obesity and Related Diseases</i> , 2017 , 13, 1990-1996	3	5
18	Pharmacokinetics and Safety of Darunavir/Ritonavir in HIV-Infected Pregnant Women. <i>AIDS Reviews</i> , 2017 , 19, 16-23	1.5	7
17	Prediction of human fetal pharmacokinetics using ex vivo human placenta perfusion studies and physiologically based models. <i>British Journal of Clinical Pharmacology</i> , 2016 , 81, 646-57	3.8	48
16	Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2016 , 65, 40-47	13.4	128
15	Bidirectional Transfer of Raltegravir in an Ex Vivo Human Cotyledon Perfusion Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 3112-4	5.9	9
14	Reply to: "Therapeutic drug monitoring for sofosbuvir and daclatasvir in transplant recipients with chronic hepatitis C and advanced renal disease". <i>Journal of Hepatology</i> , 2016 , 65, 1065-1066	13.4	0
13	Plasma concentrations of maraviroc and raltegravir after dual therapy in patients with long-term suppressed viraemia: ROCnRAL ANRS 157 study. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 2418-20	5.1	3
12	Switch to Rilpivirine/Emtricitabine/Tenofovir Single-Tablet Regimen of Human Immunodeficiency Virus-1 RNA-Suppressed Patients, Agence Nationale de Recherches sur le SIDA et les Hépatites Virales CO3 Aquitaine Cohort, 2012-2014. <i>Open Forum Infectious Diseases</i> , 2015 , 2, ofv018	1	17
11	Placental transfer of rilpivirine in an ex vivo human cotyledon perfusion model. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 2901-3	5.9	10
10	Tenofovir plasma concentrations related to estimated glomerular filtration rate changes in first-line regimens in African HIV-infected patients: ANRS 12115 DAYANA substudy. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 1517-21	5.1	9
9	Placental transfer of darunavir in an ex vivo human cotyledon perfusion model. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 5617-20	5.9	13
8	Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 1648-52	5.1	26
7	Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. <i>Clinical Infectious Diseases</i> , 2010 , 50, 773-8	11.6	307
6	Contribution and limit of the model of perfused cotyledon to the study of placental transfer of drugs. Example of a protease inhibitor of HIV: nelfinavir. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2009 , 147, 157-60	2.4	27
5	Clinical Validation of Saquinavir/Ritonavir Genotypic Resistance Score in Protease-Inhibitor-Experienced Patients. <i>Antiviral Therapy</i> , 2007 , 12, 247-252	1.6	6
4	Placental transfer of lopinavir/ritonavir in the ex vivo human cotyledon perfusion model. <i>American Journal of Obstetrics and Gynecology</i> , 2006 , 195, 296-301	6.4	39
3	Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men. <i>Aids</i> , 2004 , 18, 1958-61	3.5	76
2	Efficacy and Safety of Ritonavir/Indinavir 100/400 Mg Twice Daily in Combination with Two Nucleoside Analogues in Antiretroviral Treatment-Naive HIV-Infected Individuals. <i>Antiviral Therapy</i> , 2003 , 8, 603-609	1.6	11

1 Antiviral drugs in hospitalized patients with COVID-19 - the DisCoVeRy trial

4